Your browser is no longer supported. Please, upgrade your browser.
Nektar Therapeutics
Index- P/E- EPS (ttm)-2.48 Insider Own1.40% Shs Outstand179.09M Perf Week-6.97%
Market Cap3.11B Forward P/E- EPS next Y-2.43 Insider Trans-5.44% Shs Float177.86M Perf Month-11.21%
Income-440.70M PEG- EPS next Q-0.67 Inst Own97.80% Short Float13.60% Perf Quarter-0.33%
Sales163.30M P/S19.07 EPS this Y-166.60% Inst Trans0.10% Short Ratio23.29 Perf Half Y-30.30%
Book/sh6.54 P/B2.53 EPS next Y3.20% ROA-25.30% Target Price- Perf Year-23.93%
Cash/sh5.08 P/C3.26 EPS next 5Y-7.30% ROE-34.40% 52W Range13.63 - 25.06 Perf YTD-2.59%
Dividend- P/FCF- EPS past 5Y-42.70% ROI-26.60% 52W High-33.92% Beta1.69
Dividend %- Quick Ratio8.10 Sales past 5Y-10.60% Gross Margin87.10% 52W Low21.50% ATR0.82
Employees723 Current Ratio8.30 Sales Q/Q2.70% Oper. Margin- RSI (14)40.11 Volatility3.83% 4.42%
OptionableYes Debt/Eq0.00 EPS Q/Q-7.90% Profit Margin- Rel Volume0.66 Prev Close16.66
ShortableYes LT Debt/Eq0.00 EarningsNov 05 AMC Payout- Avg Volume1.04M Price16.56
Recom2.40 SMA20-8.05% SMA50-5.62% SMA200-15.47% Volume680,557 Change-0.60%
Jan-06-21Initiated Stifel Hold $18
Sep-14-20Initiated JP Morgan Neutral $26
Jun-10-20Downgrade CFRA Hold → Sell
May-12-20Reiterated H.C. Wainwright Neutral $32 → $26
Apr-22-20Initiated The Benchmark Company Buy $26
Mar-30-20Upgrade Goldman Sell → Neutral $18 → $20
Mar-04-20Initiated Barclays Overweight $30
Feb-03-20Upgrade Mizuho Neutral → Buy $21 → $35
Oct-24-19Initiated Oppenheimer Perform $18
Oct-08-19Downgrade Goldman Buy → Sell $54 → $16
Aug-09-19Downgrade Mizuho Buy → Neutral $79 → $21
Aug-09-19Downgrade JP Morgan Overweight → Neutral $62 → $33
Aug-09-19Downgrade Jefferies Buy → Hold $59 → $23
Mar-15-19Initiated SVB Leerink Mkt Perform $38
Dec-13-18Initiated Goldman Buy $62
Jun-11-18Downgrade H.C. Wainwright Buy → Neutral $54
Jun-04-18Reiterated H.C. Wainwright Buy $125 → $97
Apr-20-18Initiated Seaport Global Securities Buy $120
Apr-13-18Resumed Piper Jaffray Overweight $125
Apr-06-18Reiterated Mizuho Buy $89 → $103
Jan-06-21 05:00PM  
Jan-05-21 04:20PM  
Dec-22-20 11:03AM  
Dec-18-20 08:15PM  
Dec-16-20 10:45AM  
Dec-15-20 08:30AM  
Dec-08-20 06:00AM  
Dec-07-20 04:00PM  
Dec-05-20 11:32AM  
Nov-11-20 02:00PM  
Nov-10-20 06:47AM  
Nov-09-20 09:04AM  
Nov-06-20 02:01AM  
Nov-05-20 08:00PM  
Nov-04-20 10:15AM  
Oct-29-20 06:00PM  
Oct-28-20 06:00PM  
Oct-27-20 07:30AM  
Oct-05-20 03:27PM  
Sep-28-20 05:24PM  
Sep-24-20 06:47PM  
Sep-05-20 11:32AM  
Aug-12-20 09:42AM  
Aug-07-20 11:35AM  
Aug-06-20 07:00PM  
Aug-05-20 11:15AM  
Jul-30-20 12:33PM  
Jul-28-20 06:00PM  
Jun-23-20 09:46PM  
Jun-14-20 09:25PM  
Jun-06-20 11:31AM  
Jun-04-20 05:00PM  
May-29-20 05:00PM  
May-26-20 11:11AM  
May-22-20 08:30AM  
May-18-20 08:05AM  
May-17-20 07:13PM  
May-12-20 06:27AM  
May-08-20 10:29AM  
May-07-20 05:55PM  
Apr-30-20 12:33PM  
Apr-28-20 05:00PM  
Apr-09-20 06:08PM  
Apr-06-20 06:24AM  
Mar-29-20 10:51PM  
Mar-28-20 11:30AM  
Mar-11-20 09:19PM  
Mar-01-20 09:15AM  
Feb-28-20 06:30PM  
Feb-27-20 05:35PM  
Feb-20-20 12:31PM  
Feb-18-20 05:00PM  
Feb-17-20 10:27AM  
Feb-10-20 02:56PM  
Feb-06-20 05:50PM  
Feb-03-20 09:12AM  
Jan-29-20 03:46PM  
Jan-27-20 09:08AM  
Jan-24-20 07:02PM  
Jan-23-20 11:43AM  
Jan-21-20 05:53PM  
Jan-16-20 01:37PM  
Jan-15-20 04:08PM  
Jan-14-20 10:47PM  
Jan-13-20 09:14AM  
Jan-10-20 04:08PM  
Jan-07-20 09:00AM  
Dec-24-19 01:09PM  
Dec-19-19 12:21PM  
Nektar Therapeutics, a biopharmaceutical company, researches and develops drug candidates for cancer and auto-immune disease in the United States. The company develops NKTR-181, a novel mu-opioid analgesic drug, which is in Phase III clinical trial for chronic low back pain; ONZEALD, a topoisomerase I inhibitor that is in Phase III clinical trial for advanced metastatic breast cancer in patients with brain metastases; and Bempegaldesleukin, a CD122-preferential interleukin-2 (IL-2) pathway agonist, which is in Phase I is designed to provide rapid activation and proliferation of cancer-killing CD8+ effector T cells and NK cells. It also develops NKTR-358, cytokine Treg stimulant, which is in Phase I to treat autoimmune diseases; NKTR-262, a toll-like receptor agonist that is in Phase I for oncology; and NKTR-255, which is in phase I for immuno-oncology. In addition, the is developing ADYNOVATE and ADYNOVI for hemophilia A; MOVANTIK for opioid-induced constipation in adult patients with chronic non-cancer pain; CIMZIA for crohn's disease, rheumatoid arthritis, and psoriasis/ankylosing spondylitis; and MIRCERA for anemia associated with chronic kidney disease. Further, it is developing Macugen for age-related macular degeneration; Somavert for acromegaly; Neulasta for neutropenia; Dapirolizumab Pegol for systemic lupus erythematosus; PEGPH20 for pancreatic, non-small cell lung cancer, and other tumor types; and longer-acting blood clotting proteins for hemophilia. The company has collaboration agreement with Takeda Pharmaceutical Company Ltd.; AstraZeneca AB; UCB Pharma S.A.; F. Hoffmann-La Roche Ltd; Bausch Health Companies Inc.; Pfizer Inc.; Amgen Inc.; UCB Pharma (Biogen); Halozyme Therapeutics, Inc.; Bristol-Myers Squibb Company; Baxalta Incorporated; and Eli Lilly and Company, as well as with Merck KGaA. Nektar Therapeutics was incorporated in 1990 and is headquartered in San Francisco, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
GREER R SCOTTDirectorJan 05Option Exercise13.8040,000552,000225,674Jan 05 05:09 PM
Myriam CuretDirectorDec 15Sale17.821,56027,79919,240Dec 17 06:08 PM
Zalevsky JonathanChief R&D OfficerNov 23Sale16.4016,380268,632250,317Nov 25 06:09 PM
Zalevsky JonathanChief R&D OfficerNov 16Sale16.9329,618501,433266,697Nov 18 07:08 PM
Wilson Mark AndrewSVP & General CounselNov 16Sale16.931,53926,05549,850Nov 18 07:07 PM
Thomsen Jillian B.SVP & Chief Accounting OfficerNov 16Sale16.9311,976202,754159,757Nov 18 07:05 PM
ROBIN HOWARD WPresident & CEONov 16Sale16.9311,975202,737352,043Nov 18 07:04 PM
Labrucherie Gil MSVP, COO & CFONov 16Sale16.938,276140,113226,973Nov 18 07:03 PM
Ajer Jeffrey RobertDirectorSep 28Sale17.253,25056,06325,975Sep 30 07:03 PM
CHESS ROBERTDirectorSep 25Sale17.755,50097,625280,573Sep 25 08:16 PM
Ajer Jeffrey RobertDirectorSep 21Sale19.742,25044,41520,125Sep 21 08:58 PM
Labrucherie Gil MSVP, COO & CFOSep 17Sale19.962,00039,920235,249Sep 21 08:59 PM
CHESS ROBERTDirectorSep 08Option Exercise9.248,00073,920284,973Sep 10 08:19 PM
CHESS ROBERTDirectorSep 08Sale18.538,000148,240276,973Sep 10 08:19 PM
WHITFIELD ROY ADirectorSep 04Option Exercise9.2430,000277,200228,250Sep 08 06:18 PM
Labrucherie Gil MSVP, COO & CFOAug 18Sale19.682,00039,360237,249Aug 19 06:37 PM
Zalevsky JonathanChief R&D OfficerAug 17Sale19.6726,200515,354296,315Aug 19 06:41 PM
Wilson Mark AndrewSVP & General CounselAug 17Sale19.671,52930,07551,389Aug 19 06:40 PM
ROBIN HOWARD WPresident & CEOAug 17Sale19.6711,885233,778364,018Aug 19 06:38 PM
Thomsen Jillian B.SVP & Chief Accounting OfficerAug 17Sale19.671,36726,889171,733Aug 19 06:39 PM
Labrucherie Gil MSVP, COO & CFOAug 17Sale19.676,245122,839239,249Aug 19 06:37 PM
GREER R SCOTTDirectorJul 09Option Exercise9.2440,000369,600191,583Jul 10 07:06 PM
GREER R SCOTTDirectorJul 09Sale25.0015,009375,225176,574Jul 10 07:06 PM
CHESS ROBERTDirectorJul 08Option Exercise9.248,00073,920284,973Jul 10 07:05 PM
CHESS ROBERTDirectorJul 08Sale24.588,000196,640276,973Jul 10 07:05 PM
Labrucherie Gil MSVP, COO & CFOMay 19Sale22.622,00045,240245,494May 20 06:29 PM
Zalevsky JonathanChief R&D OfficerMay 18Sale22.514,558102,601322,515May 20 06:33 PM
Wilson Mark AndrewSVP & General CounselMay 18Sale22.511,52934,41852,418May 20 06:32 PM
Thomsen Jillian B.SVP & Chief Accounting OfficerMay 18Sale22.511,36730,771172,719May 20 06:31 PM
Labrucherie Gil MSVP, COO & CFOMay 18Sale22.515,727128,915247,494May 20 06:29 PM
ROBIN HOWARD WPresident & CEOMay 18Sale22.518,968201,870375,903May 20 06:30 PM
CHESS ROBERTDirectorApr 15Sale18.388,000147,010276,973Apr 17 06:03 PM
CHESS ROBERTDirectorMar 11Sale16.798,000134,316276,973Mar 13 06:04 PM
Thomsen Jillian B.SVP & Chief Accounting OfficerFeb 18Sale22.351,39431,156174,086Feb 20 06:39 PM
Zalevsky JonathanChief R&D OfficerFeb 18Sale22.354,774106,699327,073Feb 20 06:39 PM
Labrucherie Gil MSVP, COO & CFOFeb 18Sale22.355,938132,714253,221Feb 20 06:37 PM
ROBIN HOWARD WPresident & CEOFeb 18Sale22.358,448188,813384,871Feb 20 06:38 PM
CHESS ROBERTDirectorFeb 12Sale23.508,000188,000276,973Feb 14 07:00 PM
Thomsen Jillian B.SVP & Chief Accounting OfficerFeb 06Option Exercise7.2137,500270,375212,980Feb 07 07:31 PM
Thomsen Jillian B.SVP & Chief Accounting OfficerFeb 06Sale22.7837,500854,250175,480Feb 07 07:31 PM